Genmab
GMAB
209 hedge funds and large institutions have $1.37B invested in Genmab in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 81 increasing their positions, 67 reducing their positions, and 49 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 67
0% more call options, than puts
Call options by funds: $7.04M | Put options by funds: $7.01M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.66% less ownership
Funds ownership: 64.42% → 63.76% (-0.66%)
8% less funds holding
Funds holding: 227 → 209 (-18)
20% less capital invested
Capital invested by funds: $1.72B → $1.37B (-$349M)
35% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$57.8M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$50.1M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$40.6M |
| 4 |
BlackRock
New York
|
+$22.5M |
| 5 |
Capital International Investors
Los Angeles,
California
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$58.1M |
| 2 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$42.8M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$29.3M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$23.5M |
| 5 |
FAM
Fred Alger Management
New York
|
-$21.9M |
GMAB Hedge Fund Activity: Q1 2021 in Review
209 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Genmab (GMAB) for Q1 2021, worth a combined $1.37B — down 20% from $1.72B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of GMAB and 32 opened new positions — a net loss of 17 holders — while 67 trimmed existing stakes and 81 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $57.8M. The largest seller was Jennison Associates, exiting entirely with an estimated $58.1M sold.
- 209 institutional investors held Genmab (GMAB) as of Q1 2021, down from 227 in Q4 2020.
- Funds reported $1.37B of Genmab stock for Q1 2021, down 20% quarter-over-quarter.
- 32 funds opened new Genmab positions in Q1 2021 and 49 closed out, a net change of -17 holders.
- The largest Genmab buyer in Q1 2021 was T. Rowe Price Associates, an estimated $57.8M added.
- The largest Genmab seller in Q1 2021 was Jennison Associates, an estimated $58.1M sold.
Based on aggregated 13F filings for Q1 2021.